Differential invasive capacity of Providencia alcalifaciens isolates
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY The bacterial family that is particularly associated with infections of the gut are Enterobacteriaceae. One significant but understudied family member, Providencia alcalifaciens, has been linked to sporadic foodborne outbreaks of diarrhea and isolated from stool samples from persons with diarrhea. P. alcalifaciens is also part of the human oral, sputum and gut microbiomes of healthy individuals. What distinguishes commensal from enteropathogenic P. alcalifaciens? Most diarrheal isolates harbor a large plasmid ranging in size from 128 kb - 181 kb that encodes a type III secretion system (T3SS) that is closely related to, and functionally interchangeable with, the invasion-associated T3SS (T3SS1) of Salmonella enterica serovar Typhimurium. Of the plasmid- carrying isolates, a subset invades non-phagocytic host cells in cellulo. The primary objective of this application is to define what role this genomic and phenotypic heterogeneity plays in P. alcalifaciens pathogenesis. A comparative genomic analysis identified nine genes in the 40 kb type III gene cluster on the plasmid as statistically associated with the invasion phenotype. In Specific Aim 1, we will use in silico, in vitro and in cellulo analysis to determine if these predicted genes are the molecular drivers of invasiveness in P. alcalifaciens. In Specific Aim 2, we will establish an oral-challenge murine model to assess bacterial colonization and host response in the gut upon infection with invasive and non-invasive P. alcalifaciens isolates. These results will define the contribution of intestinal epithelial cell invasion to P. alcalifaciens enteropathogenesis via the natural route of infection. The potential impact of our proposed work is high because it will be the first to decipher the genetic and molecular basis of pathogenicity of P. alcalifaciens, and the first systematic assessment of P. alcalifaciens virulence determinants in a small animal model.
Grant Summary
Differential invasive capacity of Providencia alcalifaciens isolates is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $449K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $449K
2028-01-31
- 1Confirm your organization is eligible for Differential invasive capacity of Providencia alcalifaciens isolates from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Differential invasive capacity of Providencia alcalifaciens isolates: Frequently Asked Questions
Who is eligible for the Differential invasive capacity of Providencia alcalifaciens isolates?
Differential invasive capacity of Providencia alcalifaciens isolates is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Differential invasive capacity of Providencia alcalifaciens isolates provide?
Differential invasive capacity of Providencia alcalifaciens isolates provides up to $449K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Differential invasive capacity of Providencia alcalifaciens isolates deadline?
Applications for Differential invasive capacity of Providencia alcalifaciens isolates are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Differential invasive capacity of Providencia alcalifaciens isolates?
To apply for Differential invasive capacity of Providencia alcalifaciens isolates, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.